Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.70142 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Nabil K El Ayoubi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut, Beirut, Lebanon. Hauptthemen laut MEDLINE: Rituximab, Immunologic Factors, Multiple Sclerosis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti‐CD20 therapy on clinical and sub‐clinical outcomes in multiple sclerosis.
Methods
Clinical information was collected prospectively on Research Electronic Data Capture. Patients with age ≥ 18 years old, confirmed diagnosis of multiple sclerosis, treatment with B‐cell depleting drug (Rituximab and Ocrelizumab), and minimum follow‐up of 12 months with at least 3 clinical visits and at least 3 infusions of medication were included and divided into an extended interval dosing group, a standard interval dosing group, and a converters group who switched from standard to extended interval dosing. Retinal measures were obtained using spectral domain Optical Coherence Tomography. Magnetic resonance imaging acquisitions were performed in two centers using a standardized conventional imaging protocol for multiple sclerosis.
Results
Patients had a median clinical follow‐up of 3.5 (0.44–7.3) years, retinal OCT follow‐up of 2.6 (1.4) years, and MRI follow‐up of 2.6 (1.1) years. Annualized changes in clinical measures, retinal measures, and brain volumetric measures were similar between the 3 groups. Multivariate regression analyses also showed no differences.
Interpretation
We found no differences in clinical or sub‐clinical outcomes between patients treated with standard interval dosing, patients converting from standard to extended interval dosing, and patients on extended interval dosing of B‐cell depleting drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut, Beirut, Lebanon.
- Department of Neurology, American University of Beirut and Medical Center, Beirut, Lebanon.
- Department of Internal Medicine, Clinical Research Institute, American University of Beirut Medical Center, Beirut, Lebanon.
- College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
- Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
- Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
ORCID-Profile: Nabil K El Ayoubi, Salem Hannoun, Samia J Khoury
Zitieren
APA
El Ayoubi, N. K., Fahd, F., Tamim, H., Hannoun, S., Bal, M., El-Hallak, E., & Khoury, S. J. (2025). Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70142
Vancouver
El Ayoubi NK, Fahd F, Tamim H, Hannoun S, Bal M, El-Hallak E, et al. Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70142
BibTeX
@article{ElAyoubi2025,
author = {El Ayoubi, Nabil K and Fahd, Fares and Tamim, Hani and Hannoun, Salem and Bal, Mark and El-Hallak, Elham and Khoury, Samia J},
title = {Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.70142}
}
EUVIMED